Radiation Segmentectomy (RS) in Hepatocellular Carcinoma

Research by Lewandowski et al published in Radiology suggests that patients with small hepatocellular carcinomas (HCC) respond favorably to intra-arterial treatment with yttrium-90.

The authors reported outcomes from a retrospective analysis of 70 patients with HCC that were less or equal to 5 cm.  The patients received a radiation dose of more than 190 Gy.

Sixty-three patients (90%) showed response by using European Association for the Study of the Liver  (EASL) criteria, of which 41 (59%) showed complete response. Fifty patients (71%) achieved response by using World Health Organization (WHO) criteria, of which 11 (16%) achieved complete response. Response rates at 6 months were 86% and 49% by using EASL and WHO criteria, respectively. Median overall survival was 6.7 years; survival probability at 1, 3, and 5 years was 98%, 66%, and 57%, respectively. Overall survival probability at 1, 3, and 5 years was 100%, 82%, and 75%, respectively, in patients with baseline tumor size less than or equal to 3 cm (n = 45) and was significantly longer than in patients with tumors greater than 3 cm (P = .026).

The authors concluded that RS provides tumor control, and survival outcomes comparable to curative-intent treatments for patients with early-stage HCC who have preserved liver function.

MRI in Cirrhotic Patients at High Risk for Hepatocellular Carcinoma

Kim at al reported in JAMA Oncology their experience regarding the accuracy of MRI with liver specific contrast versus ultrasonography in the surveillance of patients with cirrhosis who are at high risk in developing hepatocellular carcinoma.

Ultrasonography (US) is considered the study of choice for screening patients with cirrhosis at risk of hepatocellular carcinoma.  The current recommendation is for US to be performed every 6 months.

Liver MRI was performed on a 1.5Tesla scanner and Gadoxetic acid (Primovist) was administered at a dose of 0.025 mmol/kg.  Axial T1 weighted images of the arterial, portal, delayed and hepatobilliary phases at 4-mm thickness sections were obtained.   

The authors conducted a prospective study of 407 cirrhotic patients who underwent semi-annual US and MRI studies.  The patients were followed with dynamic computed tomography 6 months after the screening imaging studies.

A total of 407 patients received 1100 screenings with both MRI and US.  Hepatocellular carcinomas were diagnosed in 43 patients.  Ultrasound diagnosed only one HCC, MRI detected 26, 11 by both, and 5 were missed by both.

The HCC detection rate of the MRI was 86%, higher than the 27.9% of US.  MRI showed significantly lower false-positive findings than US, 3% versus 5.6% of US.  Of the 43 patients with HCC 32 had a single less than 2 cm nodule and received curative treatments.  The 3-year survival of the patients with HCC (86%) was at par to those without HCC.

The 5-year survival rate of HCC is lower than 20%, and early diagnosis is essential for the possibility of a cure.  The current recommendation for patients at high risk of developing HCC is US needs to be reviewed as the  accuracy of US is low.

The authors conclude that screening of patients with cirrhosis with MRI and liver specific contrast resulted in higher HCC detection rate and fewer false positive findings when compared with US.

JAMA Oncology, Online First, September 22, 2016